Financial Information
This section houses up-to-date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Sera Prognostics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQSERA
Beta | 0.27 |
---|---|
Shares Outstanding | 31.0M |
Average Volume (10 days) | 85.4K |
Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
Current Mean Recommendation | Strong Buy |
---|
Strong Buy | 4 | |
---|---|---|
Buy | 0 | |
Hold | 1 | |
Underperform | 0 | |
Sell | 0 |
Recent Insider Transactions
Gregory C. Critchfield Director, Chief Executive Officer | 62,200 Acquire Mar 7, 2023 |
---|---|
Michael R. Foley Chief Medical Officer | 27,000 Acquire Mar 6, 2023 |
Paul Kearney Chief Data Officer | 16,000 Acquire Mar 6, 2023 |
Benjamin Jackson General Counsel | 24,700 Acquire Mar 6, 2023 |
Robert G. Harrison Chief Information Officer | 28,500 Acquire Mar 6, 2023 |
Email Alerts
Sign up for our investor relations email list here.